search
Back to results

Submucosal Saline Injection Followed by Endoscopic Ultrasound (EUS-SSI)

Primary Purpose

Esophageal Cancer

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Submucosal Saline Injection
Blue laser Imaging and Magnifying Endoscopy
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Esophageal Cancer focused on measuring Submucosal Saline Injection, Endoscopic Ultrasound, Early Esophageal Cancer, Staging

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18-75 years old, no gender limited; Patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy; Patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus; patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery; patients who understand test purpose, volunteer to join these study and sign the consent inform. Exclusion Criteria: Patients with stages of T2, T3, or T4 displayed by EUS; Patients who can't tolerate endoscopy and surgical treatment for various reasons; Patients who have distant metastasis, or multiple source of malignant tumors; Patients with blood coagulative disorder; Patients don't accept the endoscopic examination or surgical treatment; Patients with poor compliancy.

Sites / Locations

  • Cancer center, Sun Yat-sen UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

EUS only

EUS+SSI

BLI+ME/EUS+SSI

Arm Description

The enrolled patients will accept ordinary EUS only.

The enrolled patients will be accepted submucosal injection of saline(SSI),then EUS will be performed.

The enrolled patients will be accepted ordinary endoscope using blue laser Imaging and magnified ensocope system(BLI+ME), firstly. If B3 type intra pillary capillary loops (IPCL) was observed, then the procedure would be finished (no EUS or EUS+SSI) . If B1 or B2 type IPCL was observed, then EUS+SSI would be performed.

Outcomes

Primary Outcome Measures

Diagnostic accuracy for T1a and T1b staging
The stages judged from EUS or EUS+SSI or BLI+ME/EUS+SSI will be compared with the pathological results after endoscopic or surgical resection. So the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of the three groups for early esophageal cancer will be measured respectivly.

Secondary Outcome Measures

Full Information

First Posted
August 28, 2023
Last Updated
August 28, 2023
Sponsor
Sun Yat-sen University
Collaborators
Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Shandong Cancer Hospital and Institute, Xinqiao Hospital of Chongqing, Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT06022978
Brief Title
Submucosal Saline Injection Followed by Endoscopic Ultrasound
Acronym
EUS-SSI
Official Title
Submucosal Saline Injection Followed by Endoscopic Ultrasound Versus Endoscopic Ultrasound Only for Distinguishing Between T1a and T1b Esophageal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
December 30, 2024 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University
Collaborators
Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Shandong Cancer Hospital and Institute, Xinqiao Hospital of Chongqing, Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Endoscopic ultrasound (EUS) is unsatisfactory in distinguishing between T1a and T1b stage esophageal squamous cell carcinoma (ESCC). Consequently, the National Comprehensive Cancer Network guidelines recommend endoscopic resection (ER) as a diagnostic tool for substaging T1 stage ESCC. However, as an invasive approach, diagnostic ER is not an optimal approach especially for T1b cases as most of them might not be fully cured by ER. It is necessary to develop reliable and less invasive methods to distinguish between T1a and T1b stage ESCC. In our previous unicentral trial, we found that submucosal saline injection (SSI) significantly improved the diagnostic accuracy of EUS in differentiating between T1a and T1b stage ESCC. It can be used as an alternative to diagnostic ER for preoperative substaging T1 stage ESCC cases in remote regions where few endoscopists are able to perform diagnostic ER. The use of EUS and SSI would help T1b stage patients avoid invasive diagnostic ER. Therefore, we aim to conduct a multi-center clinical trail to examine whether SSI can improve traditional EUS accuracy in distinguishing between T1a and T1b stage ESCC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Cancer
Keywords
Submucosal Saline Injection, Endoscopic Ultrasound, Early Esophageal Cancer, Staging

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
432 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EUS only
Arm Type
No Intervention
Arm Description
The enrolled patients will accept ordinary EUS only.
Arm Title
EUS+SSI
Arm Type
Experimental
Arm Description
The enrolled patients will be accepted submucosal injection of saline(SSI),then EUS will be performed.
Arm Title
BLI+ME/EUS+SSI
Arm Type
Experimental
Arm Description
The enrolled patients will be accepted ordinary endoscope using blue laser Imaging and magnified ensocope system(BLI+ME), firstly. If B3 type intra pillary capillary loops (IPCL) was observed, then the procedure would be finished (no EUS or EUS+SSI) . If B1 or B2 type IPCL was observed, then EUS+SSI would be performed.
Intervention Type
Procedure
Intervention Name(s)
Submucosal Saline Injection
Intervention Description
Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
Intervention Type
Procedure
Intervention Name(s)
Blue laser Imaging and Magnifying Endoscopy
Intervention Description
It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
Primary Outcome Measure Information:
Title
Diagnostic accuracy for T1a and T1b staging
Description
The stages judged from EUS or EUS+SSI or BLI+ME/EUS+SSI will be compared with the pathological results after endoscopic or surgical resection. So the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of the three groups for early esophageal cancer will be measured respectivly.
Time Frame
Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-75 years old, no gender limited; Patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy; Patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus; patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery; patients who understand test purpose, volunteer to join these study and sign the consent inform. Exclusion Criteria: Patients with stages of T2, T3, or T4 displayed by EUS; Patients who can't tolerate endoscopy and surgical treatment for various reasons; Patients who have distant metastasis, or multiple source of malignant tumors; Patients with blood coagulative disorder; Patients don't accept the endoscopic examination or surgical treatment; Patients with poor compliancy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jian-jun Li, M.D.
Phone
86-2087342822
Email
lijj@sysucc.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jian-jun Li, M.D.
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cancer center, Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jian-jun Li, M.D.
Phone
86-2087343381
Email
lijj@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Jian-jun Li, M.D.

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Submucosal Saline Injection Followed by Endoscopic Ultrasound

We'll reach out to this number within 24 hrs